A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients

Inclusion Criteria: * Patients voluntarily participated in the study and signed informed consent. * male and female subjects aged ≥18 years old (when signing the informed consent); * Moderate to severe hidradenitis suppurativa: Hurley stage II or III. * Patients voluntarily participated in the study and signed informed consent. * male and female subjects aged ≥18 years old (when signing the informed consent); * Moderate to severe hidradenitis suppurativa: Hurley stage II or III. * Participants had stable disease at screening and baseline, with lesions located in ≥2 anatomical areas (≥1 at Hurley stage II/III), a total of ≥3 abscesses and inflammatory nodules (AN), and C-reactive protein levels \> 3.0 mg/L. * Participants had to have an intolerance, contraindication, or inadequate response to ≥3 months of oral antibiotic treatment for HS or relapse after discontinuation of treatment. * Informed consents were signed according to the spirit of the Declaration of Helsinki. * agree to receive regular treatment, follow-up, and relevant laboratory examinations in accordance with the clinical research protocol. Exclusion Criteria: * Allergy to drugs or excipients; * patients who had previously used cubitumumab or tofacitinib; * At the time of screening, the medical history, symptoms and examination results of the subjects suggested that the patients had active tuberculosis, active hepatitis B (HBV DNA\> lower limit), hepatitis C, syphilis (TPPA+ but excluding active syphilis negative) or AIDS. * any active malignant tumor or history of malignant tumor within 5 years, except cured skin squamous cell carcinoma or basal cell carcinoma or cervical cancer in situ; * Severe infection or systemic infection requiring intravenous anti-infection therapy or hospitalization due to infection within 4 weeks before baseline; * Severe, progressive or uncontrolled liver disease, defined as AST or ALT elevation \> 3 times, or total bilirubin ULN elevation \>2 times, which can be rescreened after treatment; * Baseline drainage tube count \> 20, diagnosis of inflammatory diseases other than HS, and history of chronic or recurrent infection or malignant tumor; * history of drug abuse, attempted suicide or mental illness; * those who participated in other clinical trials in the past 3 months; * pregnant, breastfeeding, or planning to become pregnant during the trial; * other conditions that the investigators thought should not be included.